Tools for Assessing the Protective Efficacy of TB Vaccines in Humans: <i>in vitro</i> Mycobacterial Growth Inhibition Predicts Outcome of <i>in vivo</i> Mycobacterial Infection.

ABSTRACT: Tuberculosis (TB) remains a leading global cause of morbidity and mortality and an effective new vaccine is urgently needed. A major barrier to the rational development of novel TB vaccines is the lack of a validated immune correlate or biomarker of protection. Mycobacterial Growth Inhibition Assays (MGIAs) provide an unbiased measure of ability to control mycobacterial growth in vitro, and may represent a functional correlate of protection. However, the biological relevance of any potential correlate can only be assessed by determining the association with in vivo protection from either a controlled mycobacterial infection or natural development of TB disease. Our data demonstrate that the direct MGIA using peripheral blood mononuclear cells (PBMC) is measuring a biologicall

SUBMITTER: Tanner R 

PROVIDER: S-EPMC6968127 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature